What does sentinel node positivity mean for prognosis?

A positive sentinel node confirms cancer has spread to at least one lymph node. For melanoma this upgrades staging to stage III, opening eligibility for adjuvant immunotherapy (pembrolizumab, nivolumab) or targeted therapy (dabrafenib/trametinib for BRAF-mutated tumours). For breast cancer it influences adjuvant chemotherapy, radiotherapy field design, and surveillance planning.

How accurate is sentinel node biopsy compared to complete lymph node dissection?

Sentinel node biopsy has a false-negative rate of approximately 5-10%, meaning a small proportion of patients with a negative SLNB have occult disease in non-sentinel nodes. However, randomised trials (MSLT-I for melanoma, NSABP B-32 for breast cancer) demonstrated equivalent long-term survival outcomes compared to immediate complete lymph node dissection, with far lower morbidity.

Can a predictive calculator replace sentinel node biopsy?

No. Predictive calculators provide population-based probability estimates - they cannot definitively determine whether an individual's sentinel node contains tumour. A calculated risk of 8% means biopsy will be negative in approximately 92 of 100 similar patients, but it cannot identify which 8 will be positive. Biopsy with pathological examination remains the only definitive staging method.

What is the significance of the MSLT-I and MSLT-II trials for melanoma sentinel node biopsy?

MSLT-I (Morton et al., 2014) established that SLNB provides accurate regional staging and identified the subset who benefit from further nodal treatment, with equivalent melanoma-specific survival to ELND. MSLT-II demonstrated that completion lymph node dissection after a positive SLNB did not improve melanoma-specific survival compared to active nodal surveillance with ultrasound, fundamentally changing post-SLNB management.

How does histological grade affect sentinel node positivity in breast cancer?

Grade 3 (poorly differentiated) breast cancers have higher nodal positivity rates in some series, though the relationship is modulated by receptor status and increasing use of neoadjuvant chemotherapy. Higher grade correlates with more aggressive proliferative biology and larger tumour burden, both of which predict regional spread. Grade is most meaningful as a risk factor when integrated with tumour size, LVI, and receptor status rather than considered in isolation.

What happens to patients after a negative sentinel node biopsy - do they need further follow-up?

A negative sentinel node biopsy indicates no detectable nodal disease at the time of surgery, but regular oncological follow-up remains essential. For melanoma, guidelines recommend clinical examination and surveillance imaging at defined intervals for several years, as distant recurrence can occur even after negative SLNB. For breast cancer, ongoing surveillance for local and distant recurrence follows standard protocols. The frequency and modality of surveillance depend on primary tumour characteristics and institutional protocols.

Are there populations where sentinel node biopsy has lower accuracy?

Accuracy is lower in patients with prior surgery or radiation to the regional nodal basin, obesity, or anatomically complex drainage territories such as head and neck melanoma. The false-negative rate is higher when fewer than two nodes are removed or when pathological examination does not include serial sectioning and immunohistochemistry. In these scenarios, the multidisciplinary team must weigh the reduced staging accuracy against the clinical benefit of attempting the procedure.

What is multifocal breast cancer and does it increase sentinel node positivity?

Multifocal breast cancer refers to multiple ipsilateral tumour foci within the same quadrant (multifocal) or different quadrants (multicentric). Multiple foci may increase the overall burden of disease and have been associated with higher nodal positivity rates in some series, though evidence remains mixed. Current guidelines generally support sentinel node biopsy for multifocal disease confined to the breast, though the identification rate may be lower and the surgical approach requires careful planning with the oncology team.

What is the sentinel node identification rate and what factors affect it?

In experienced centres using dual tracer technique (radioisotope and blue dye), identification rates exceed 95%. Factors that reduce identification rates include prior surgery or radiation to the regional basin, obesity, advanced age, and anatomically complex drainage territories such as head and neck melanoma or medial quadrant breast tumours. Single tracer techniques achieve slightly lower rates of approximately 88-93%. High identification rates require sufficient institutional volume and experienced nuclear medicine and surgical teams working in close collaboration.

What does it mean if the sentinel node contains isolated tumour cells (ITC)?

Isolated tumour cells (ITC) are defined as clusters smaller than 0.2 mm or fewer than 200 cells, classified as pN0(i+). Their prognostic and therapeutic significance remains debated. For breast cancer, ITC were not an indication for CLND in the Z0011 population. For melanoma, sub-micrometastases are being studied in MSLT-II sub-group analyses. Most contemporary guidelines treat ITC as a staging finding of uncertain significance requiring multidisciplinary discussion rather than automatic escalation of treatment.

How does SLNB integrate into multidisciplinary cancer care?

Sentinel node biopsy is typically planned and reviewed within a multidisciplinary team (MDT) setting that includes surgical oncologists, medical oncologists, radiation oncologists, radiologists, nuclear medicine physicians, and pathologists. The decision to offer SLNB, the technical approach, pathological processing protocol, and management of positive results are all discussed at MDT level. For patients, this means multiple specialists review their case before and after the procedure, ensuring that staging information translates into the most appropriate and evidence-based treatment plan.

What is the sentinel node positivity rate for thin melanomas (less than 1 mm)?

For melanomas thinner than 0.8 mm without adverse features, the sentinel node positivity rate is approximately 3-5% - below most guideline thresholds for routine SLNB. For T1b melanomas (0.8-1.0 mm, or any T1 with ulceration or mitotic rate of 1/mm2 or higher), positivity rates range from approximately 5-12%, placing them in the zone where SLNB is discussed individually. Young age, Clark level IV-V, and regression are additional thin melanoma features that may prompt SLNB discussion even below the 0.8 mm threshold in some centres.

Sentinel Node Positivity Calculator- Free SLNB Risk Assessment Tool

Sentinel Node Positivity Calculator – Free SLNB Risk Assessment Tool | Super-Calculator.com

JavaScript Required

This sentinel node positivity calculator requires JavaScript to estimate SLN biopsy positivity risk for melanoma and breast cancer. Please enable JavaScript in your browser to use this free SLNB risk assessment and surgical oncology staging tool.

Important Medical Disclaimer

This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.

Sentinel Node Positivity Calculator

Estimate sentinel lymph node biopsy (SLNB) positivity risk for cutaneous melanoma and early-stage breast cancer. Enter primary tumour characteristics to receive an evidence-based SLN positivity probability, five-tier risk ladder classification, and clinical guidance aligned with NCCN and ESMO guidelines.

Patient Parameters

Breslow Thickness

0.8 – 1.0 mm

Adverse Features

None

Ulceration

Mitotic Rate (per mm2)

Lymphovascular Invasion

10%

Estimated SLN Positivity Risk

High Risk

Where Your Risk Falls on the Sentinel Node Positivity Spectrum

Low <5%

Inter-
mediate

High Risk Zone – 10% to 65%

SLN Positivity Risk Tier Classification

Very Low – less than 3%

SLNB generally not indicated

Low – 3% to 5%

Discuss adverse features with patient

Intermediate – 5% to 10%

Individualised clinical decision

High – 10% to 25%

SLNB generally recommended

Very High – greater than 25%

SLNB strongly recommended

Clinical Guidance

SLNB is generally recommended at this risk level. A positive result will confirm stage III disease and open eligibility for adjuvant systemic therapy.

Estimates based on MSLT-I data and published multi-institutional SLNB series. Results should inform, not replace, specialist clinical assessment.

Reference table showing estimated sentinel lymph node positivity rates by tumour type and primary characteristics, based on published MSLT-I and multi-institutional SLNB series data.

Tumour Type	Primary Characteristic	Estimated SLN Positivity	SLNB Recommendation

Detailed breakdown of the clinical and pathological criteria used in this calculator, their evidence base, and the magnitude of their effect on sentinel node positivity risk.

Factor	Tumour Type	Effect on SLN Risk	Evidence Source
Breslow thickness <0.8 mm	Melanoma	~3% positivity rate – below most guideline thresholds	AJCC 8th ed.; MSLT-I sub-group data
Breslow thickness 0.8-1.0 mm	Melanoma	~5-8% baseline; discuss with adverse features	NCCN v2025; ESMO 2024 guidelines
Breslow thickness 1.01-2.0 mm	Melanoma	~12-18% positivity; SLNB standard of care	Morton et al. NEJM 2014 (MSLT-I)
Breslow thickness 2.01-4.0 mm	Melanoma	~23-32% positivity; SLNB strongly indicated	MSLT-I pooled analysis
Breslow thickness >4.0 mm	Melanoma	~35-44% positivity; high systemic risk context	MSLT-I; Gershenwald et al. 2017
Ulceration present	Melanoma	~1.5-2.0x multiplier on base Breslow risk	Balch et al. 2009; AJCC 8th ed.
Mitotic rate 1/mm2	Melanoma	+2 percentage points above base risk	Azzola et al. 2003; AJCC 7th ed.
Mitotic rate 2-4/mm2	Melanoma	+4 percentage points above base risk	Pooled series analysis
Mitotic rate 5+/mm2	Melanoma	+6 percentage points above base risk	Pooled series analysis
Lymphovascular invasion	Melanoma	+5 percentage points above base risk	Published institutional series
T1a (<5 mm)	Breast cancer	~3-5% positivity; SLNB may not be indicated	NSABP B-32; ALMANAC trial
T1b (5-10 mm)	Breast cancer	~8-12% positivity; SLNB generally indicated	NSABP B-32; pooled series
T1c (11-20 mm)	Breast cancer	~15-22% positivity; SLNB standard of care	NSABP B-32; ALMANAC trial
T2 (21-50 mm)	Breast cancer	~28-38% positivity; SLNB strongly indicated	NSABP B-32; published series
Grade 2 vs Grade 1	Breast cancer	+3 percentage points above T-stage base	Published institutional series
Grade 3 vs Grade 1	Breast cancer	+6 percentage points above T-stage base	Published institutional series
LVI present	Breast cancer	+12 percentage points above base risk	Carter et al.; published series
Multifocal disease	Breast cancer	+4 percentage points above base risk	Published institutional series
All estimates represent population averages from published series. Individual results vary by centre volume, pathological protocol, and patient characteristics.

Published sentinel lymph node positivity rates across diverse populations and tumour subtypes, based on multi-centre trials and institutional series from North America, Europe, and Asia-Pacific.

Population / Subtype	SLN Positivity Range	Key Observations	Reference
Melanoma, all T stages (US cohort)	15-20% overall	Identification rate 98.5%; median follow-up 10 years	MSLT-I, Morton et al. NEJM 2014
Melanoma, T1b (0.8-1.0 mm)	5-12%	Adverse features (ulceration, mitosis) substantially increase risk	Pooled analysis, Sondak et al. 2021
Melanoma, T2 (1.01-2.0 mm)	12-22%	Most common SLNB indication; highest volume category	MSLT-I; European series
Melanoma, nodular subtype	+5-8% vs superficial spreading	More aggressive vertical growth phase; higher positivity at equal Breslow thickness	Published histological subtype analyses
Melanoma, acral lentiginous	Variable; lower frequency	Common in East and South Asian populations; distinct biology from cutaneous melanoma	Kim et al. 2018; Asian melanoma consortium
Melanoma, head and neck	15-25% (drainage pattern complexity)	False-negative rate higher due to complex cervical lymphatic anatomy	MSLT-I head-neck sub-group
Breast cancer, all cT1-2 cN0 (US)	27% overall positive	Identification rate 97.2%; false-negative rate 9.8%	NSABP B-32, Krag et al. LANCET 2010
Breast cancer, T1a (<5 mm)	3-5%	Some centres omit SLNB for T1a; institutional variation	Published series; SSO position statement
Breast cancer, triple negative	Higher in T1c-T2 range	More aggressive biology; frequent neoadjuvant chemotherapy alters nodal rate	Published TNBC cohort series
Breast cancer, HER2-positive	Similar to luminal B	Neoadjuvant trastuzumab frequently used; post-NAC SLNB has higher FNR	SENTINA trial sub-group analysis
Breast cancer, luminal A (ER+/PR+/HER2-)	Lower within T stage	Slower biology; LVI uncommon; grade typically 1-2	Published molecular subtype analyses
General SLNB identification rate	95-99% in high-volume centres	Dual tracer (radioisotope and blue dye) required for highest rates	SLNB systematic review, Ahmed et al. 2018
SLNB false-negative rate	5-10% across indications	Does not translate to worse survival in randomised trial populations	MSLT-I; NSABP B-32 combined analysis

No assessments logged yet. Complete a calculation and click “Log Current Assessment” to save it here.

Important Medical Disclaimer

About This Sentinel Node Positivity Calculator

This sentinel node positivity calculator is designed for surgical oncologists, medical oncologists, oncology nurses, and informed patients seeking an evidence-based estimate of sentinel lymph node biopsy (SLNB) positivity risk before surgery. It covers the two most common and best-validated clinical applications: cutaneous melanoma and early-stage breast cancer. For melanoma, the tool incorporates Breslow thickness, histological ulceration, mitotic rate, and lymphovascular invasion – the primary determinants of nodal spread identified through the Multicenter Selective Lymphadenectomy Trial I (MSLT-I) and subsequent pooled series. For breast cancer, it applies tumour size T stage, histological grade, lymphovascular invasion, and multifocality in line with data from the NSABP B-32 and ALMANAC trials.

The calculator uses a risk stratification model derived from published institutional series and landmark randomised controlled trials to produce a probability estimate, a five-tier risk ladder from very low to very high, and a clinical action recommendation per risk tier. The zone bar places the estimated percentage precisely on the low-to-high sentinel node positivity spectrum so clinicians and patients can visualise where an individual’s tumour characteristics fall relative to published guideline thresholds. The parameter panel identifies which specific pathological features are driving elevated risk, and the assessment log tab allows multiple clinical scenarios to be compared within the same session.

Using this tool alongside the clinical criteria and population norms tabs – which display reference positivity rates from MSLT-I, NSABP B-32, ALMANAC, and other published trials – helps contextualise the estimate within the broader oncological evidence base. As with all risk calculators, the output is a population-level probability and should be interpreted in conjunction with full clinical assessment, multidisciplinary team review, and patient preferences. It does not replace pathological examination of the sentinel node, which remains the definitive staging method.

Sentinel Lymph Node Biopsy Calculator – Complete Clinical Guide to SLN Positivity Risk Assessment

Sentinel lymph node biopsy (SLNB) has transformed the surgical management of solid tumours, providing accurate regional staging without the morbidity of complete lymph node dissection. The sentinel node – the first draining lymph node from a primary tumour – serves as a biological proxy for the entire nodal basin. When the sentinel node is clear, the remaining nodes are almost certainly free of disease. When it is positive, further treatment decisions follow. Knowing the probability of sentinel node positivity before surgery helps clinicians counsel patients, plan operative approaches, and weigh the benefits of the procedure against its risks.

This calculator estimates the likelihood of sentinel lymph node positivity for two of the most common applications: cutaneous melanoma and early-stage breast cancer. It draws on validated predictive models and established clinical guidelines to provide an evidence-based risk estimate. The result should be interpreted alongside full clinical assessment and discussed with an experienced multidisciplinary oncology team.

What Is a Sentinel Lymph Node?

The sentinel lymph node concept was first described by Cabanas in 1977 in the context of penile carcinoma, and subsequently popularised by Morton and colleagues for melanoma in 1992. The principle rests on the observation that lymphatic drainage from a primary tumour follows a predictable anatomical pathway. The first node encountered along this path – the sentinel node – acts as a gatekeeper. Tumour cells, if they spread via lymphatics, will lodge in the sentinel node before progressing to more distal nodes.

Intraoperative identification of the sentinel node relies on two complementary techniques: intradermal injection of a vital blue dye (such as isosulfan blue or patent blue) and injection of a radiolabelled colloid (typically technetium-99m sulphur colloid). The blue-stained or radioactive node is removed and examined by pathology using serial sectioning and immunohistochemistry – methods far more sensitive than routine histology of a full axillary or inguinal dissection specimen.

Why Sentinel Node Biopsy Matters

Regional lymph node status remains one of the most powerful prognostic determinants across multiple tumour types. For melanoma, nodal involvement drives upstaging from stage II to stage III disease and directly influences eligibility for adjuvant systemic therapies, including immune checkpoint inhibitors and targeted BRAF/MEK combinations. For breast cancer, axillary nodal status guides decisions on adjuvant chemotherapy, radiotherapy field design, and reconstruction planning.

Before SLNB became standard, surgeons performed complete elective lymph node dissection (ELND) for staging. ELND carries significant risks: lymphoedema in up to 30% of patients, wound infection, seroma formation, numbness, and restricted limb movement. Because only 15-30% of melanoma patients with intermediate-thickness tumours actually harbour nodal disease, the majority underwent a major procedure with significant morbidity for no staging benefit. SLNB identifies the subset who truly need further intervention while sparing the rest.

Key Point: The 5-10% Rule

When sentinel node positivity risk falls below 5%, most guidelines consider SLNB optional rather than standard-of-care. Between 5% and 10%, the decision requires individualised discussion. Above 10%, SLNB is generally recommended unless contraindicated. This calculator helps clinicians identify which risk tier a patient falls into.

Melanoma Sentinel Node Positivity – Predictive Factors

The single strongest predictor of sentinel node positivity in melanoma is Breslow thickness – the measured depth of tumour invasion from the granular cell layer of the epidermis to the deepest tumour cell. Morton’s landmark Multicenter Selective Lymphadenectomy Trial I (MSLT-I) demonstrated that Breslow thickness correlates closely with nodal positivity rates across a continuous spectrum.

Additional tumour features that independently predict nodal disease include mitotic rate – the number of mitoses per square millimetre of tumour section. A rate of 1/mm2 or higher was incorporated into the AJCC 7th edition as an independent adverse prognostic factor and correlates strongly with sentinel node positivity. Histological ulceration – defined as full-thickness absence of the epidermis overlying any part of the tumour – roughly doubles nodal positivity rates independent of thickness and is a defining feature of T1b melanoma under AJCC 8th edition criteria. Lymphovascular invasion, where tumour cells appear within lymphatic channels on histology, also independently predicts a higher probability of regional spread.

Melanoma SLN Positivity Estimation – Key Thickness Thresholds

Breslow 0.8-1.0 mm (no ulceration): ~5-8% SLN positivity
Breslow 1.01-2.0 mm: ~12-18% SLN positivity
Breslow 2.01-4.0 mm: ~23-32% SLN positivity
Breslow greater than 4.0 mm: ~35-44% SLN positivity
Ulceration present: multiply estimate by ~1.5 to 2.0x

Estimates derived from MSLT-I data (Morton et al., 2014) and pooled multi-institutional series. Mitotic rate, lymphovascular invasion, and patient age further modulate these baseline estimates.

Breast Cancer Sentinel Node Positivity – Predictive Factors

For early-stage breast cancer, the axillary sentinel node biopsy has largely replaced routine axillary dissection following the landmark ACOSOG Z0011 and SENTINA trials. The probability of sentinel node positivity depends on a constellation of primary tumour characteristics, some of which also predict outcome after systemic therapy.

Tumour size (T stage) is the primary determinant: T1a tumours (less than 5 mm) have less than 5% positivity, while T2 tumours (greater than 2 cm) may exceed 30%. Peritumoural lymphovascular invasion (LVI) on core biopsy or surgical specimen is a strong independent predictor of axillary involvement, adding approximately 10-15 percentage points to the background size-based risk. Histological grade, multifocality, receptor status, and patient age contribute additional, if smaller, effects.

Breast Cancer SLN Positivity – Tumour Size Correlation

T1a (less than 5 mm): ~3-5% SLN positivity
T1b (5-10 mm): ~8-12% SLN positivity
T1c (11-20 mm): ~15-22% SLN positivity
T2 (21-50 mm): ~28-38% SLN positivity
LVI present: add approximately 10-15 percentage points

Estimates derived from NSABP B-32 (Krag et al., LANCET 2010) and ALMANAC trial data. Apply only to patients proceeding directly to surgery without prior neoadjuvant chemotherapy.

Validated Predictive Models and Nomograms

Several research groups have developed multivariate nomograms to integrate multiple clinical and pathological factors into a single probability estimate. The Memorial Sloan Kettering Cancer Center (MSKCC) melanoma sentinel node nomogram, published by Kattan and colleagues, incorporates Breslow thickness, Clark level, ulceration, mitotic rate, site, gender, and histological subtype. External validation studies have demonstrated acceptable discrimination with areas under the ROC curve of 0.67-0.72 in independent cohorts.

For breast cancer, the MSKCC breast nomogram for predicting sentinel node status integrates tumour size, histological type, nuclear grade, lymphovascular invasion, multifocality, age, and oestrogen receptor status. All such nomograms perform better than any single clinical variable alone, though none achieves sufficient discriminatory ability to completely replace biopsy in clinical practice.

Key Point: No Model Replaces Biopsy

Predictive models identify patients at low, intermediate, or high risk – they do not provide the definitive staging that pathological examination delivers. A model predicting 4% positivity still means 1 in 25 patients harbours occult nodal disease. Clinical context, patient preferences, and institutional expertise must inform the final decision alongside any calculated estimate.

Current Clinical Guidelines Summary

The major international oncology bodies provide consensus guidance on sentinel node biopsy indications, though specific thresholds evolve as new trial data emerge.

Organisation	Tumour Type	SLNB Recommendation Threshold
NCCN (USA)	Melanoma	Breslow greater than 1.0 mm; discuss at 0.8-1.0 mm with ulceration or high mitotic rate
ESMO (Europe)	Melanoma	Breslow greater than 1.0 mm standard; Breslow 0.75-1.0 mm with adverse features
NCCN (USA)	Breast cancer	cT1-2 cN0 tumours; avoid in cT3-4 or clinically node-positive
ESMO (Europe)	Breast cancer	cT1-2 cN0; SLNB preferred over axillary dissection for clinically node-negative patients
SSO/ASCO	Melanoma	Strongly recommend for T2-T4; individualise for T1b with Breslow 0.8-1.0 mm

Consequences of a Positive Sentinel Node

When the sentinel node contains metastatic tumour, the clinical implications depend on tumour type, metastasis burden within the node, and evolving trial data. For melanoma, the MSLT-II trial demonstrated that completion lymph node dissection (CLND) did not improve melanoma-specific survival compared to active surveillance with regular ultrasound imaging, though it did reduce nodal recurrence rates. The positive SLNB result still upgrades patients to stage III, opening eligibility for adjuvant pembrolizumab or nivolumab (immune checkpoint inhibitors) or adjuvant dabrafenib/trametinib for BRAF-mutated tumours.

For breast cancer, the ACOSOG Z0011 trial established that in women meeting specific criteria (cT1-2 breast cancer treated with breast conservation surgery and whole-breast radiotherapy, with one or two positive sentinel nodes), CLND could be safely omitted without detriment to survival. CLND remains indicated for patients with three or more positive sentinel nodes, those undergoing mastectomy, or those with extracapsular extension of nodal disease.

Complications and Risk Profile of SLNB

Sentinel node biopsy carries a substantially lower complication profile than complete nodal dissection, but it is not without risk. Lymphoedema occurs in approximately 5-8% of patients after SLNB, compared to 15-30% after complete axillary dissection. Wound infection affects approximately 2-4%, seroma formation 5-15% (more common in axillary procedures), and anaphylaxis from blue dye occurs in approximately 1 in 500 to 1 in 1,000 procedures. Failed sentinel node identification occurs in 2-5% of cases.

Global Application and Population Considerations

Sentinel node biopsy techniques and outcome data have been validated across diverse populations in North America, Europe, Asia-Pacific, and other regions. Melanoma epidemiology varies substantially by geography: rates are highest in Australia and New Zealand, while melanoma in East and South Asian populations more commonly presents on acral surfaces with distinct biology compared to cutaneous melanoma in lighter-skinned populations. Breast cancer is the most common cancer in women globally, and SLNB has been implemented as standard practice across diverse healthcare systems. The fundamental predictive relationships between tumour size, grade, lymphovascular invasion, and nodal positivity are consistent enough across ethnic groups that validated nomograms retain reasonable performance globally.

Interpreting Your Calculator Result

The sentinel node positivity probability generated by this calculator represents a population-level estimate based on tumour characteristics known to predict nodal disease. A result of 15% means that approximately 15 out of every 100 patients with this combination of features will have a positive sentinel node. The calculator cannot tell you which individual will fall into which group – only the biopsy itself can answer that question definitively. Use the result as a starting point for discussion with your oncology team, not as a substitute for it.

Frequently Asked Questions

What is a sentinel lymph node biopsy and why is it performed?

A sentinel lymph node biopsy (SLNB) is a surgical procedure that removes and examines the first one to three lymph nodes draining a primary tumour. These sentinel nodes are identified using a combination of blue dye and a radioactive tracer injected near the tumour site before surgery. If tumour cells have spread through lymphatics, they are most likely to be found in the sentinel node first. A negative result gives high confidence that the rest of the lymph node basin is clear, avoiding the need for a complete lymph node dissection with its associated morbidity. A positive result confirms regional spread and guides adjuvant treatment decisions.

What does sentinel node positivity mean for my prognosis?

A positive sentinel node means cancer cells have spread to at least one lymph node. For melanoma, this upgrades the diagnosis from stage II to stage III, which is associated with lower five-year survival rates compared to node-negative disease. However, stage III melanoma is now treated with effective adjuvant immunotherapy or targeted therapy that substantially improves outcomes. For breast cancer, a positive sentinel node influences decisions on adjuvant chemotherapy, extended radiation fields, and ongoing surveillance, but one or two positive nodes under specific conditions does not necessarily require further axillary surgery. Prognosis depends on many factors beyond nodal status, including tumour biology, response to treatment, and overall health.

At what Breslow thickness is sentinel node biopsy recommended for melanoma?

Most major guidelines, including those from the NCCN and ESMO, recommend sentinel node biopsy as standard care for melanomas with Breslow thickness greater than 1.0 mm. For melanomas between 0.8 and 1.0 mm (classified as T1b under AJCC 8th edition when associated with ulceration or a mitotic rate of 1/mm2 or higher), SLNB is discussed and offered based on individual risk assessment. For melanomas thinner than 0.8 mm without adverse features, SLNB is generally not recommended because the positivity rate is low enough that the procedural risk outweighs the staging benefit in most patients.

Does ulceration affect sentinel node positivity risk in melanoma?

Yes, ulceration is a consistently recognised independent risk factor for sentinel node positivity in melanoma. Histological ulceration – defined as loss of the epidermis overlying part of the primary tumour – roughly doubles the risk of nodal disease compared to a non-ulcerated melanoma of equivalent Breslow thickness. Ulceration is also an independent adverse prognostic factor for overall survival. Under the AJCC 8th edition, ulceration drives upstaging from T1a to T1b and from T2a to T2b. When ulceration is present, clinicians typically have a lower threshold for recommending sentinel node biopsy, even in thinner tumours approaching the 0.8 mm threshold.

How does lymphovascular invasion influence sentinel node risk?

Lymphovascular invasion (LVI) – the presence of tumour cells within lymphatic or vascular channels adjacent to the primary tumour on histological examination – is a strong independent predictor of sentinel node positivity across both melanoma and breast cancer. In breast cancer series, LVI increases nodal positivity risk by approximately 10-20 percentage points above the background risk for that tumour size and grade. In melanoma, intralymphatic tumour cells are similarly associated with higher sentinel node positivity rates. LVI detection depends on the quality of pathological examination; immunohistochemistry for lymphatic markers improves identification rates.

What happens if no sentinel node can be identified during surgery?

Failed sentinel node identification occurs in approximately 2-5% of procedures even in experienced centres. When no sentinel node is found, the surgeon typically proceeds with sampling of the most likely nodal territory based on anatomical landmarks, or accepts incomplete staging and discusses the implications with the patient. In melanoma, pre-operative lymphoscintigraphy usually maps the drainage basin clearly enough to guide surgical exploration. Advances including super-paramagnetic iron oxide particles as an alternative to radioactive tracers may improve identification in resource-limited settings.

Is sentinel node biopsy appropriate after neoadjuvant chemotherapy?

Sentinel node biopsy after neoadjuvant chemotherapy (NAC) in initially node-positive breast cancer patients carries a substantially higher false-negative rate (up to 12-14%) compared to upfront SLNB. The SENTINA and SN FNAC trials examined this approach. To reduce the false-negative rate after NAC, dual mapping with both tracers, removal of three or more sentinel nodes, and targeted axillary dissection (marking the originally positive node before chemotherapy) are recommended. For melanoma, NAC is less commonly used and SLNB after targeted therapy in stage III disease remains an area of active investigation.

What does a micrometastasis versus macrometastasis in the sentinel node mean?

The AJCC defines isolated tumour cells (ITC) as clusters fewer than 0.2 mm or fewer than 200 cells (pN0(i+)); micrometastases as deposits between 0.2 and 2.0 mm (pN1mi); and macrometastases as deposits greater than 2.0 mm (pN1). For breast cancer, the Z0011 trial demonstrated that CLND could be omitted for patients with one or two positive sentinel nodes meeting its specific criteria. For melanoma, sub-micrometastases (less than 0.1 mm) are being studied in MSLT-II sub-group analyses to determine whether these patients need further nodal intervention. The size and anatomical location of deposits within the sentinel node influence recurrence risk and treatment intensity.

Can a predictive calculator replace the sentinel node biopsy procedure?

No. Predictive calculators and nomograms provide population-based probability estimates – they cannot definitively determine whether an individual patient’s sentinel node contains tumour. A calculated risk of 8% means that biopsy will be negative in approximately 92 out of 100 similar patients, but it cannot identify which 8 will have positive results. The biopsy itself, with pathological examination including serial sectioning and immunohistochemistry, remains the only definitive staging method. Calculators serve a valuable role in guiding the decision about whether to offer biopsy and informing patient counselling about expected yield.

How long does sentinel node biopsy surgery take and what are the risks?

Sentinel node biopsy typically adds 30-60 minutes to the primary tumour excision procedure. Specific risks include an approximately 5-8% risk of lymphoedema (significantly lower than complete dissection), wound infection in 2-4%, seroma formation in 5-15% (especially axillary procedures), temporary or permanent paraesthesia near the incision, and a 1 in 500 to 1 in 1,000 risk of anaphylaxis from blue dye. Most patients are discharged the same day or after one night in hospital.

What is the difference between sentinel node biopsy and complete lymph node dissection?

Sentinel node biopsy removes only one to three sentinel nodes using tracer-guided identification, providing accurate regional staging with minimal disruption to the nodal basin. Complete lymph node dissection (CLND) removes all nodes in the relevant basin – typically 10-25 nodes in the axilla for breast cancer or 8-15 nodes in the groin for melanoma. CLND carries substantially higher morbidity: lymphoedema in 15-30% of patients compared to 5-8% after SLNB. Randomised trials (MSLT-II for melanoma, ACOSOG Z0011 for breast cancer) showed CLND does not improve survival over surveillance in appropriately selected patients with low sentinel node tumour burden.

Does patient age influence sentinel node positivity rates?

Age influences sentinel node positivity in complex ways. For melanoma, younger patients (under 40) have higher nodal positivity rates for equivalent Breslow thickness, possibly reflecting more aggressive tumour biology or host immune factors. Older patients may have lower positivity rates due to impaired lymphatic function, though they are also at higher risk of procedural complications. For breast cancer, younger patients tend to present with higher-grade tumours and more aggressive subtypes. Age alone is not a sufficient reason to withhold or mandate SLNB; overall fitness, comorbidities, and the likely impact of staging on treatment decisions matter more.

What is the sentinel node false-negative rate and what does it mean clinically?

The false-negative rate (FNR) of SLNB is the proportion of patients with tumour in non-sentinel nodes who have a negative sentinel node result. Across published melanoma and breast cancer series, the FNR averages 5-10%. This does not typically translate into worse survival – MSLT-I and NSABP B-32 showed equivalent survival between SLNB and CLND groups despite the FNR. This likely reflects the low biological potential of residual occult micrometastases, which are controlled by systemic adjuvant therapies. The FNR is lowest in high-volume centres using dual tracer mapping and intensive pathological protocols.

How is the sentinel node identified during surgery?

Two complementary techniques are used. A radioisotope – typically technetium-99m-labelled sulphur colloid or nanocolloid – is injected intradermally or peritumorally on the day before or morning of surgery. The injected colloid migrates through lymphatics to the sentinel node, which is then localised with a handheld gamma probe during the operation. A vital blue dye (patent blue V, isosulfan blue, or methylene blue) is also injected around the tumour at the start of surgery; the dye flows through lymphatics within minutes and stains the sentinel node blue. The surgeon removes any node that is radioactive or visibly blue-stained, typically one to three nodes.

Do high mitotic rates significantly increase sentinel node positivity risk?

Yes, mitotic rate is an independently significant predictor of sentinel node positivity in melanoma, established across multiple institutional series. A mitotic rate of 1 per square millimetre or higher identifies melanomas with more aggressive proliferative biology and correlates with higher rates of regional and distant metastasis. The AJCC 8th edition incorporated mitotic rate directly into T1b classification for thin melanomas. Pooled analyses suggest that each unit increase in mitotic rate adds approximately 2-4 percentage points to the baseline sentinel node positivity probability, though the relationship is not strictly linear.

Is sentinel node biopsy safe in pregnant patients?

Blue dyes (isosulfan blue and patent blue V) are contraindicated in pregnancy due to theoretical foetal risk. Technetium-99m-labelled colloids can be used at reduced doses during pregnancy – the radiation dose to the foetus is estimated at less than 0.0043 Gy, well below threshold doses associated with foetal harm. Radioisotope-only SLNB during pregnancy is permitted per SSO and NCCN guidelines when staging is clinically necessary, accepting the lower identification rate as a reasonable tradeoff. Coordination between the surgical team, nuclear medicine, obstetrics, and radiation safety is essential.

What is meant by nodal tumour burden and how does it affect treatment decisions?

Nodal tumour burden refers to the size, number, and anatomical distribution of metastatic deposits within sentinel and non-sentinel lymph nodes. The MSLT-II trial and DeCOG-SLT trial demonstrated that patients with low nodal tumour burden (particularly sub-micrometastases under 0.1 mm) had very low rates of non-sentinel node involvement, supporting active surveillance over CLND in this group. For breast cancer, total nodal burden informs decisions on radiotherapy field extension and systemic therapy intensification.

How does tumour site on the body affect sentinel node drainage patterns?

Tumour location significantly influences which nodal basin or basins the sentinel node procedure must address. Lower limb melanomas drain to the inguinal basin; upper limb melanomas drain to the axilla. Head and neck melanomas may drain to multiple cervical nodal groups or to the parotid region. Truncal melanomas present the greatest complexity – a midline back melanoma may drain to one or both axillae, one or both groins, or combinations thereof. For breast cancer, most primary tumours drain to the ipsilateral axilla, but medial quadrant tumours may also drain to the internal mammary chain. Pre-operative lymphoscintigraphy maps these patterns before surgery.

What adjuvant treatments become available after a positive sentinel node in melanoma?

A positive sentinel node biopsy confirms stage III melanoma and opens eligibility for approved adjuvant therapies. Pembrolizumab (anti-PD-1 immunotherapy) is approved for resected stage IIB-IV melanoma and reduces the risk of distant recurrence by approximately 40% relative to placebo. Nivolumab is similarly approved. For patients with BRAF V600E or V600K mutations – present in approximately 50% of cutaneous melanomas – adjuvant dabrafenib plus trametinib reduces recurrence risk by approximately 53% relative to placebo in randomised trials. The choice depends on mutation status, side effect preferences, and patient comorbidities.

What is the role of ultrasound-guided biopsy versus sentinel node biopsy for lymph node staging?

Ultrasound-guided fine needle aspiration or core biopsy of suspicious lymph nodes and sentinel node biopsy serve complementary roles. If a node is clearly suspicious on ultrasound and biopsy confirms metastasis, the patient is already staged as node-positive and SLNB is unnecessary. However, ultrasound misses approximately 15-25% of positive nodes detected by SLNB, particularly in nodes that appear normal on imaging. For this reason, SLNB remains the definitive minimally invasive staging procedure for patients with sonographically normal nodes at intermediate to high risk of occult nodal disease.

How does the MSKCC melanoma nomogram estimate sentinel node positivity?

The Memorial Sloan Kettering Cancer Center (MSKCC) melanoma sentinel node nomogram integrates seven variables: Breslow thickness, Clark level, ulceration, mitotic rate, tumour site, gender, and histological subtype. The variables are scored on a nomogram scale and summed to produce an estimated probability of sentinel node positivity. External validation in several independent European, Australian, and American cohorts has demonstrated acceptable calibration and discrimination with c-statistics of approximately 0.68-0.72. The nomogram is freely available through the MSKCC website and has influenced clinical decision-making guidelines.

What is the difference between a negative sentinel node and a clear surgical margin?

These refer to different dimensions of surgical staging and local control. Surgical margins describe the tissue surrounding the primary tumour after excision – a negative margin means no cancer cells at the cut edges, reducing local recurrence risk. A negative sentinel node indicates that the regional lymph nodes examined contain no detectable metastatic tumour. A patient can have clear surgical margins but a positive sentinel node, or vice versa. Both pieces of information are independent and both influence oncological management.

Can this calculator be used for recurrent or previously treated cancer?

No. This calculator is designed for primary, previously untreated tumours where sentinel node biopsy is being considered as part of initial surgical staging. It should not be applied to in-transit recurrences, local recurrences after prior surgery, or patients who have already received neoadjuvant systemic therapy, as these scenarios fundamentally alter the lymphatic drainage anatomy and nodal biology in ways the predictive model does not account for.

What percentage of melanoma patients with Breslow thickness over 1 mm will have a positive sentinel node?

Across published SLNB series, approximately 15-20% of melanoma patients with Breslow thickness 1.01-2.0 mm have a positive sentinel node. This rises to approximately 23-32% for thickness 2.01-4.0 mm and 35-44% for thickness greater than 4.0 mm. Adverse features including ulceration, high mitotic rate, and lymphovascular invasion increase these rates. These figures are why SLNB is considered standard care above 1.0 mm – the staging yield is sufficient to justify the procedural risk in the majority of patients.

What is the ACOSOG Z0011 trial and how does it affect breast cancer sentinel node management?

ACOSOG Z0011 was a landmark randomised trial showing that in women with cT1-2 breast cancer treated with breast conservation surgery, whole-breast radiotherapy, and adjuvant systemic therapy who had one or two positive sentinel nodes, omitting completion axillary dissection did not reduce disease-free or overall survival. This paradigm-shifting result has been widely adopted, though CLND remains indicated for patients with three or more positive sentinel nodes, those undergoing mastectomy, or those with extracapsular nodal extension.

How should I interpret this calculator result?

The sentinel node positivity probability from this calculator represents a population-level estimate based on tumour characteristics known to predict nodal disease. A result of 15% means approximately 15 out of 100 patients with this combination of features will have a positive sentinel node. The calculator cannot determine which individual will fall into which group – only the biopsy itself can answer that definitively. Use the result as a starting point for discussion with your oncology team, not as a substitute for specialist clinical assessment and multidisciplinary team review.

Conclusion

Sentinel lymph node biopsy represents one of the most significant technical advances in surgical oncology over the past three decades. By focusing pathological scrutiny on the most informative lymph node in each patient’s drainage basin, it delivers accurate regional staging at a fraction of the morbidity of complete nodal dissection. The decision to perform SLNB is guided by the expected probability of a positive result – high enough to justify the procedure’s risks and costs, balanced against the staging information it will provide and the treatments it will enable.

This calculator estimates that probability using the primary tumour characteristics most strongly associated with nodal disease in validated clinical datasets. It covers the two most common and best-validated applications: cutaneous melanoma and early-stage breast cancer. For other tumour types, or for patients with complex presentations, the estimate may not apply, and specialist multidisciplinary discussion is particularly important.

The calculated probability is an estimate – a guide for clinical reasoning, not a substitute for the pathological examination that only the biopsy itself can provide. Share this result with your oncology team. Use it to start an informed conversation about whether sentinel node biopsy is right for you or your patient.